NAD+ Without Prescription: The Route Most Lifters Take

NAD+ without prescription is not one question. It is three transactions wearing the same search term: a research vial bought online, a compounded preparation written for a named patient, and an infusion administered at a clinic. Only one of them is genuinely prescription-free, and it is the one with the least oversight.

NAD+ without prescription: three transactions, not one

Separate the routes first, because most confusion online comes from two people arguing about different ones.

Only the first row is prescription-free.

That differs from the peptides covered elsewhere here. With retatrutide without prescription there is no prescription to skip, because no lawful route exists at all. NAD+ has one, which changes the question to which route you are on.

What FDA Category 1 actually says

This is where competing pages get it wrong, so it is worth quoting rather than summarizing.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacist or physician may compound using a bulk drug substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug product, or appears on FDA's 503A bulks list. NAD+ does not clear those routes, so it falls under FDA's interim policy instead, which sorts nominated substances into three categories while the agency evaluates them.

FDA's description of Category 1 is precise: these "may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list." And the operative sentence: "FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met." That wording is published on FDA's page on bulk drug substances used in compounding under section 503A.

On the category list itself, updated May 14, 2026, Nicotinamide Adenine Dinucleotide (NAD) appears in Category 1, as does Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH). There is no NAD entry in Category 2.

Now the three things that sentence does not say, each of which gets misreported.

It is not approval. Category 1 is a statement about enforcement discretion, not a finding of safety or efficacy. FDA has not concluded that NAD+ belongs on the bulks list; it has said it will not act against compounders while it decides, subject to conditions.

It is not permanent. The category is literally titled "Bulk Drug Substances Under Evaluation." FDA states that Category 1 substances may continue within the interim policy until the agency decides on inclusion, or unless it removes them based on, for example, information about safety risks. The list moves in practice: the same document records GHK-Cu being removed from Category 1 on April 22, 2026 after its nominations were withdrawn, then being added back for non-injectable routes after a nominator clarified its intent in May 2026. A status quoted from a page written last year may simply be out of date.

It is not a rule about you. The policy addresses compounders. It creates no consumer right to buy NAD+ and says nothing about a research vial bought online, which is a different transaction entirely.

If you have read that NAD+ or NADH is "Category 2" or "banned from compounding," that is a straightforward error, and a common one. Category 2 covers substances FDA has flagged for significant safety risks, and neither NAD nor NADH is on it.

The Beta-NAD trap: same words, different category

There is a genuine trap a few pages later in the same PDF, and it catches careful readers rather than careless ones.

Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate appears in Category 3, not Category 1. Category 3 covers substances nominated with insufficient supporting information for FDA to evaluate them, and FDA is explicit about what follows: "These substances are not eligible for the policy that applies to substances in category 1. FDA would consider taking action against a compounder for compounding drug products with this bulk drug substance under its general enforcement policies."

To a reader, beta-NAD looks like the same thing described more precisely. On the FDA list it is a separate entry with a different status. This is why a screenshot of a category listing proves less than people assume, and why the entry name has to be matched exactly.

One more piece of context: FDA has stated it does not intend to place substances nominated on or after January 7, 2025 into these categories at all. The system is a closing window rather than a growing register, another reason a status quoted without a date is worth little.

Is NAD+ legal to buy as research material?

For the research-vial route the position rests on two facts. NAD+ is not a controlled substance in the United States: no scheduling, no DEA registration requirement, no criminal exposure attached to possessing it. And it is not an approved drug, which means suppliers sell it as a research chemical labeled for laboratory use only and not for human consumption.

That labeling is not decoration; it is the condition under which the sale is lawful. A supplier that markets NAD+ for human injection, prints dosing on the vial or makes therapeutic claims has stepped outside that framing, which is a red flag about the seller rather than a convenience for the buyer.

What the law does not do is bless what happens afterward. Buying is not using, and a lawful purchase does not make self-administration of an unapproved substance sensible or supervised. The buying framework applied to real listings is on NAD+ where to buy, with the channel comparison on where to buy NAD+.

What the compounded route requires

What stands behind the compounded route also explains the price gap between a clinic preparation and a $52.00 vial. A compounder working under section 503A is not simply buying powder. FDA states that bulk drug substances used in compounding "must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA under section 510" of the FD&C Act, and the agency urges compounders to know their bulks supplier. The Category 1 non-enforcement position applies only where the conditions in the guidance are met.

Then there is the compounding itself: a sterile preparation made under controlled conditions, with release testing, labeling, beyond-use dating and a prescription for a named patient behind it. That work is why the clinic figure is a large multiple of the vial figure, as NAD+ price sets out.

It is also why FDA's food-grade warning is so pointed. Every one of those controls sits downstream of the bulk material, and if the material entering the process was made to a food specification, the controls do not retroactively fix it.

NAD+ no prescription means nobody is checking but you

FDA's notice on ingredients suitable for sterile compounding, content current as of 10/30/2024, reports that the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products," that food-grade ingredients "are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins," and that FDA "has received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue with some requiring medical treatment," consistent with excessive endotoxin levels. It is published on FDA's compounding pages.

Those failures happened inside the supervised route, with a pharmacist and a clinician in the chain. Remove them and the only person left to read the certificate of analysis is the buyer.

So the single question that replaces the prescriber is this: does the certificate report a bacterial endotoxin result for the lot you received, or does it stop at identity and HPLC purity? Purity tells you the powder is NAD+ and mostly NAD+. It cannot see endotoxin, which is a separate assay with a separate cost, and it is the one that maps onto the reactions FDA logged. A supplier publishing two independent lab reports per batch has at least made the documents available; whether an endotoxin figure appears on them is what to read before paying. The weighting behind that judgment is on best NAD+ source.

Precursors are a different purchase, not a legal workaround

NMN and NR are sold openly as supplements, which invites the thought that they are the prescription-free version of the same thing. They are precursors in NAD+ biosynthesis, and they are separate substances with their own regulatory history, which this article has not verified and will not assert. What can be said is that a precursor capsule is not the same purchase as injectable NAD+, and a supplement aisle is not a legal shortcut to one.

What a lifter is actually signing up for

NAD+ is a coenzyme at the center of energy metabolism, and none of that biochemistry is disputed. Clinics market infusions against tiredness, brain fog and flat sessions, and that marketing is real. The leap from settled biochemistry to "an infusion improves how a training block goes" is not, and no regulatory category makes it so. Category 1 says FDA is still evaluating; it does not say the compound works.

Taking that route with your eyes open is a coherent decision, and not a small one. The things that reliably move fatigue and work capacity across a block are duller: managed weekly load, sleep, and energy availability, covered in resistance training and myostatin and sleep, cortisol and myostatin. The prescription-free question lands differently for a compound whose bulk nomination was withdrawn rather than left under review, which we set out in Semax without prescription.

Dosing arithmetic is deliberately absent here. Peptide Dosage covers it at NAD+ dosage and the NAD+ calculator.

Frequently asked questions